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Abstracts / Biol Blood Marrow Transplant 20 (2014) S104eS127S118quintile was associated with a 40% decrease in the risk of
engraftment failure (OR 0.60, 95% CI 0.41-0.87). Even when
adjusted for cell dose infused, a higher # of collected CD34+
cells was associated with decreased time to platelet
engraftment (HR1.15, CI 1.00-1.32, p¼.052), but not ANC
engraftment (HR 1.07, p¼.35). Positive blood cultures within
30 days of ASCT were associated with engraftment failure
(p¼.0035), while race, sex, # of collections for the trans-
planted dose and mobilization regimen did not appear to
affect engraftment. We also observed that prior Imid use
demonstrated a trend toward less engraftment failure (OR
0.41, 95%CI 0.17-1.01; p¼.052).
Although a moderate correlation was observed between
the variables CD34 cells collected and CD34 cells infused, a
sensitivity analysis by omitting either variable did not iden-
tify a signiﬁcantly different estimates.153
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Background: The collection of a minimum number of he-
matopoietic stem cells (HSC), generally deﬁned as 2 x 106
CD34+ cells/kg, is a prerequisite for proceeding to HSCT.
Primary mobilization failure occurs in 5 e 40% of patients.1-5
When used to unselected patients undergoing a ﬁrst mobi-
lization attempt, plerixafor plus GCSF allows more CD34+
cells to be mobilization with fewer aphereses than GCSF
alone.6, 7 There are no publications describing the patterns of
plerixafor use at Canadian transplant centres, nor is there
data to guide determinations of cost-effectiveness of mobi-
lization using plerixafor from the Canadian perspective.
Methods: The objectives of this study were to: 1) Summa-
rize the published studies of plerixafor-based mobilization
during compassionate access programs, and 2) Describe the
Canadian experience with plerixafor during its availability
though Health Canada’s Special Access Program (SAP). A
literature search was performed and studies were grouped
into three strategies: upfront, preemptive and salvage. In
Canada, plerixafor was available through the SAP, and fun-
ded by Genzyme/Sanoﬁ from September 2008 to December
2010.
Results: Thirteen articles were identiﬁed. In all but one
study, plerixafor was used as part of a preemptive and/or
salvage strategy. The proportion lf patients in whom a min-
imum of 2 x 106 CD34+ cells/kg was collected ranged from 37
e 100%. At the time of publication, 17 e 87% of patients had
proceeded to transplantation.
Thirteen Canadian centres provided data on a total of 132
patients, the majority of whom had multiple myeloma or
lymphoma, and had undergone a median of 1 prior mobili-
zation attempt (range 0 e 3). Plerixafor was used preemp-
tively in 23 (17%) patients and as salvage in 109 (83%)
patients. In 96 (73%) patients, therewas successful collection.
Of the 23 patients in whom plerixafor was used preemp-
tively, 19 (83%) had successful collections. Of the 109 patients
in whom the drug was used as part of a salvage strategy,
77 (71%) had successful collections. Of the entire cohort,
99 (75%) of patients went on to receive an autologous
transplant.Discussion: Our study summarizes the published experience
with plerixafor-based mobilization during compassionate
drug access programs and describes the Canadian experience
when plerixafor was freely available through Health Cana-
da’s SAP. Canadian practice was similar to published inter-
national experience.
Plerixafor use decreased signiﬁcantly when it was no
longer freely available. This may be a reﬂection of limited
resources, a lack of belief in the preemptive use of plerixafor
or knowledge of the most cost-effective way to use it. The
pharmacoeconomics of mobilization likely vary from centre
to centre and are affected by multiple factors such as the
patient population, infrastructure, available resources, and
who is paying for plerixafor.154
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Background: Collection of a minimum number of hemato-
poietic progenitor cells (HPC), usually deﬁned as 2 x 106
CD34+ cells/kg, is required to ensure timely neutrophil and
platelet recovery.1-4 The majority of centres use peripheral
blood-mobilized HPCs as the source of progenitor cells for
autologous transplantation,5 but the method used to predict
the ﬁnal apheresis product CD34+ cell content, and thus the
whole blood volume to process during apheresis collection,
has not been standardized. In the mid-1990s, Mitterer et al.
demonstrated on a 28-patient cohort that the correlation
between the pre-apheresis peripheral blood CD34+ cell
count and the number of CD34+ cells/kg collected could be
used to determine the blood volume to process during
apheresis to harvest the desired number of CD34+ cells/kg
(target-value tailored, TVT, collection). Using this concept
and local data, the Ottawa Canadian Blood Services Stem Cell
Laboratory created a similar regression model to help
determine the blood volume to process during apheresis
collection.
Methods: We conducted a retrospective study of all pe-
ripheral blood HPC apheresis collections performed at the
Ottawa Hospital from January 1, 2003 to December 31, 2011.
Our objective was to validate the TVT approach, as modiﬁed
by our institution.
Results: From 2003 to 2011, there were 815 peripheral blood
HPC collections by apheresis. The majority, 696 (85.4%), were
autologous collections and 119 (14.6%) were allogeneic do-
nors. The most common diagnoses were multiple myeloma
and aggressive non-Hodgkin lymphoma (NHL). The median
age of the cohort was 51.1 (range 14.3 e 70.4) years. The
median number of prior chemotherapy regimens was 1
(range 0 e 5). The majority of collections, 635 (93.7%), were
ﬁrst attempts.
The median pre-collection peripheral blood CD34+ cell
count was 2.23 (interquartile range, IQR 1.07 e 5)/mL. The
Table 1.0 Collection of autologous stem cells
Chemo-
mobilization
Cytokine
mobilization
p-value
Median CD34 cells/kg
collected (in millions/kg)
14.9 8.37 .009
Median number
of apheresis days (mean)
2
(2.13)
1
(1.76)
.29
Target dose achieved:
Yes
No
13 (81.3%)
3 (18.8%)
34 (91.9%)
3 (10%)
.26
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(88.7%) collections one day of apheresis was required to
achieve the minimum number of HPCs. The median apher-
esis volume for day 1 collections was 20 (range 3.6 e 24) L.
The correlation coefﬁcient between the pre-collection pe-
ripheral blood CD34+ cell count and the ﬁnal product CD34+
cell content is 0.69 (p<.001; Figure 1). The TVT estimate was
highly predictive of the ﬁnal product CD34+ count (r¼0.82,
p<.0001; Figure 2). Aminimumof 2 x 106 CD34+ cells/kgwas
collected in 90.4% of collections.
Discussion: Using the correlation between the pre-collec-
tion peripheral blood CD34+ count and the ﬁnal product HPC
content, the TVT formula can accurately determine the blood
volume to process during apheresis collection. This has
resulted in reduced apheresis time, fewer apheresis days, and
less nursing time. Ultimately, the TVT formula has allowed
our program to improve our resource utilization by accu-
rately predicating the required apheresis volume.155
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Background: Autologous stem cell mobilization can be
achieved using chemo-mobilization (CHM) or growth factors
alone (cytokine-mobilization, CTM). Mobilization with peg-
ﬁlgrastim and “just-in-time” plerixafor has been shown to be
a successful strategy. Experience with pegﬁlgrastim and
planned plerixafor is limited. We here describe our experi-
ence using two mobilization strategies with pegﬁlgrastim
plus plerixafor (CTM) or cyclophosphamide, pegﬁlgrastim
plus plerixafor (CHM).
Methods: We retrospectively identiﬁed patients who
received an auto-SCT for a diagnosis of myeloma at TJU be-
tween July 2010 and June 2013. These 53 patients who had
stem cell mobilization using either CHM (16 patients) with
cyclophosphamide (4 grams/m2), pegﬁlgrastim (12 mg) and
plerixafor (0.24 mg/kg once daily until target dose collected
or maximum of 4 days of apheresis), or CTM with pegﬁl-
grastim plus plerixafor (37 patients). Plerixafor was only
administered as an outpatient. We hypothesized that more
patients in the CHM group reached the prescribed total
CD34-positive stem cell collection as compared to the CTM
group. To test this hypothesis we used the two-sample test
on proportions. For the comparison of the median total CD34
cells/kg dose collection and the median number of apheresis
days we used the Wilcoxon rank sum test and the t-test,
respectively.
Results: There was no difference in patient age at transplant,
sex, and myeloma subtype. The median number of prior in-
duction therapies was similar; there was no signiﬁcant dif-
ference in the prior exposure to lenalidomide, however as
expected, bone marrow plasmacytosis was higher in theCHM group (6% vs. 2%). In the CHM group, 41% were hospi-
talized due to complication (typically neutropenic fevers)
and thus only 9 patients (59%) received the planned dose of
plerixafor as compared to 100% in the CTM group. Therewere
no hospitalizations in the CTM group due to toxicity. CHM
was associated with a signiﬁcantly higher median total
CD34+ cell collection (14.9 x 106/kg vs. 8.37 x 106/kg,
p¼0.009) (Table 2). CTM is associated with fewer collection
days (median 1 day vs. 2 days, p¼.29) and more patients
achieving the target CD34+ cell dose of 6.0 x 106/kg (91.9% vs.
81.3%, p¼.26).
Conclusion: The preferred method to mobilize autologous
stem cells should be with pegﬁlgrastim and planned plerix-
afor since it is able to achieve the prescribed cell dose, is
associated with less toxicity and risk of hospitalization. This
analysis suggests that per 100 patients collected a total of 100
days of plasmaphresis could be avoided if all patients were
mobilized with growth factors alone.156
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Background: Patients (pt) with advanced stage and high
International Prognostic Index (IPI) or relapsed/primary re-
fractory diffuse large B-cell lymphoma (DLBCL) have an
adverse prognosis and are frequently consolidated with
autologous stem cell transplantation (SCT).
Aim: Evaluation of a single center experience with SCT in
DLBCL.
Methods: Retrospective analysis of outcome of adult pt
submitted to SCT in DLBCL, between October 1992 and
December 2012. Data were collected from the database and
the medical records.
Results: 152 SCT were performed in various histological
subtypes of DLBCL, during this time period. Statistical anal-
ysis was performed in 113 pt with "classical" DLBCL and
histological variants were excluded.
Median age at SCT was 49 years (16-67), 68 males/45
females. At diagnosis the majority of pt were in advanced
stage (85%) and had an IPI 2 or 3 (47%, 30% respectively).
